compound 4c

compound 4c is a synthetic small molecule investigated primarily as a succinate receptor antagonist. It is listed as a surrogate/experimental drug with no approved uses and no known brand names. The molecule has also been referred to as BMS compound 4c in select research contexts. Its structure is detailed on pharmacological databases, and chemical properties include a molecular weight of 470.1 Da, 6 hydrogen bond acceptors, and 1 hydrogen bond donor[5][3][10]. No bioactivity data is available in major therapeutic indications, and no clinical approvals are known. Research also links compound 4c to DprE1 inhibition and, in the context of benzothiazolyl piperidine-3-carboxamide derivatives, inhibitory activity against multiple cyclin-dependent kinases (CDK2, CDK5, CDK6)[7][9].

Other names

BMS compound 4c